TransMedics (TMDX) Reports Q2 Earnings: What Key Metrics Have to Say

For the quarter ended June 2026, TransMedics (TMDX) reported revenue of $189.95 million, up 20.7% over the same period last year. EPS came in at $0.44, compared to $0.92 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $184.17 million, representing a surprise of +3.14%. The company delivered an EPS surprise of -12%, with the consensus EPS estimate being $0.50.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how TransMedics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• OCS transplant revenue- United States- Total: $183.62 million versus $177.1 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +20.7% change.
• OCS transplant revenue- United States- Lung total revenue: $2.25 million versus the three-analyst average estimate of $2.83 million.
• OCS transplant revenue- United States- Heart total revenue: $33.38 million compared to the $30.21 million average estimate based on three analysts.
• OCS transplant revenue- United States- Liver total revenue: $147.99 million versus the three-analyst average estimate of $144.05 million.
• OCS transplant revenue- All other countries- Total: $5.24 million compared to the $5.15 million average estimate based on three analysts. The reported number represents a change of +26% year over year.
• OCS transplant revenue- All other countries- Lung total revenue: $0.41 million compared to the $0.48 million average estimate based on three analysts.
• OCS transplant revenue- All other countries- Heart total revenue: $4.59 million compared to the $4.5 million average estimate based on three analysts.
• OCS transplant revenue- All other countries- Liver total revenue: $0.25 million compared to the $0.26 million average estimate based on two analysts.
• Revenue- Service: $78.79 million versus the two-analyst average estimate of $69.04 million. The reported number represents a year-over-year change of +28.6%.
• Revenue- Net Product: $111.16 million versus the two-analyst average estimate of $113.35 million. The reported number represents a year-over-year change of +15.7%.

View all Key Company Metrics for TransMedics here>>>

Shares of TransMedics have returned +14.5% over the past month versus the Zacks S&P 500 composite's +1.7% change. The stock currently has a Zacks Rank #5 (Strong Sell), indicating that it could underperform the broader market in the near term.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research